Disha’s Weekly Wisdom: Ten factors that are driving pharma
Disha Chakraborty of WhatPackaging? opines we need low-cost patent-free vaccines for global health.
18 Apr 2024 | By Disha Chakraborty
India needs low-cost patent-free vaccines for global health.
Disha Chakraborty of WhatPackaging? opines we need low-cost patent-free vaccines for global health.
- In March 2024, the pharmaceutical market experienced a 6.4% growth compared to April 2023, resulting in a turnover of Rs 1.98 trillion. However, domestic market volumes saw a 1% decline during this period.
- The overall pharma supply chain, logistics and warehousing costs in India is 15% higher worldwide plus the Indian pharma companies have an inventory period of 98 days over 64% global data.
- A glance at the numbers published by World Health Organisation (WHO) reveals that the global biopharmaceuticals packaging market, starting at USD 17.86 billion in 2022. This anticipates growth, projecting the market to reach USD 42.08 billion by 2032, marking a CAGR of 9.0% between 2023 and 2032.
- The Indian pharma industry plays a leading role globally, with 10% share of world production volumes and 2.4% share globally in terms of value. Exports are more than 50% of the total Indian pharma industry turnover and help provide affordable healthcare through high quality yet affordable generic drugs and formulations. Growth in pharma has boosted the packaging market.
- The country’s top five firms account a turnover of USD 1.5-bn, over average spend of USD 7-bn by firms on R&D. The five pharma firms are: Dr. Reddy’s, Biocon, Alembic Pharmaceuticals, Cipla, Sun Pharma.
- The pharma industry must invest in R&D to accomplish the goal, which will take over ten years.
- According to Venture Intelligence, offline retailers (more than 8,00,000 in India) are resentful about online pharmacies being allowed to sell habit-forming drugs, anti-tubercular drugs, and higher antibiotics.
- In the past year, all therapies have resulted in positive values other than the respiratory therapies. Cardiac showed volume growth around 7.5% followed by at antibiotics at 6.8% and gastrointestinal intestinal at 5.8%.
- The WHO states that approximately half of the drugs sold online are counterfeit. Between 1-30% of all drugs available on the market are counterfeit, with a lower percentage occurring in developed nations and a higher percentage in developing nations.
- One of the big players in the pharma industry aims to increase its market share by 2-3%, which could result in a higher EBITDA rating. Additionally, it has retained its "Reduce" rating with an assigned fair value of Rs 4,800. This suggests that despite its efforts to grow its market share, analysts still believe the company stock is overvalued and recommend reducing exposure to it.